FDA Liver Disease Guidance Gets Boost From Sponsor-Sponsored Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The American Association for the Study of Liver Diseases hopes upcoming workshop will spur regulatory transparency necessary to stimulate nonalcoholic fatty liver disease (NAFLD) drug development.